Browsing by Author de Boer, Richard

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2009Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancerWilcken, Nicholas; Boyle, Frances; Chan, Arlene; Craft, Paul; de Boer, Richard; Mainwaring, Paul; McCarthy, Nicole; Snyder, Raymond; Western Clinical School: Medicine (Westmead)Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer, Asia Pacific Journal of Clinical Oncology, vol.5, 1,pp 4-16
2016Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscapeBeith, Jane; Bell, Richard; Burslem, Katie; de Boer, Richard; Loi, Sherene; McCarthy, Nicole; Redfern, Andrew; Woodward, Natasha; Central Clinical School: MedicineHormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape, Asia-Pacific Journal of Clinical Oncology, vol.12, Suppl.1, 2016,pp 3-18
2016Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscapeBeith, Jane; Bell, Richard; Burslem, Katie; de Boer, Richard; McCarthy, Nicole; Redfern, Andrew; Woodward, Natasha; Central Clinical School: MedicineHormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape, Asia-Pacific Journal of Clinical Oncology, vol.12, Suppl. 1, 2016,pp 19-31
2012A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancerClarke, Stephen; Pavlakis, Nick; Clingan, Philip R.; de Boer, Richard; Johnston, Michael; Michael, Michael; Concord Clinical School: Medicine; Northern Clinical School: MedicineA multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer, Oncology reports, vol.28, 3, 2012,pp 763-767
2014Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectivesWilcken, Nicholas; Beith, Jane M.; Bell, Richard; Chirgwin, Jacquie; Chua, Sue; Colosimo, Maree; de Boer, Richard; Francis, Prudence; Green, Michael; Pittman, Kenneth; White, Michelle; Zdenkowski, Nicholas; Western Clinical School: Medicine (Westmead)Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives, Asia-Pacific Journal of Clinical Oncology, vol.10, Suppl S4, 2014,pp 15-25
2014Systemic treatment of HER2-positive metastatic breast cancer: A systematic reviewWilcken, Nicholas; Beith, Jane; Bell, Richard; Chirgwin, Jacquie; Chua, Sue; Colosimo, Maree; de Boer, Richard; Francis, Prudence; Green, Michael; Mainwaring, Paul; Pittman, K; Snyder, Raymond; White, Michelle; Zdenkowski, Nicholas; Western Clinical School: Medicine (Westmead)Systemic treatment of HER2-positive metastatic breast cancer: A systematic review, Asia-Pacific Journal of Clinical Oncology, vol.10, S4, 2014,pp 1-14